Open-label Pilot Study of Abatacept for the Treatment of Vitiligo

Summary

Vitiligo is a chronic autoimmune disease with evidence of CTLA-4 involvement. We are performing a pilot study for the treatment of new onset or actively progressing vitiligo with abatacept to determine if weekly self-injections of medication lead to clinical improvement in vitiligo lesions.

Timeline

Start

2015-01

Primary completion

2017-11

Completion

2018-05

Drugs

Indications